- Preclinical-stage oncology focused company Nuvation Bio, will combine with Panacea Acquisition Corp., a special purpose acquisition company sponsored by EcoR1 Capital; CEO David Hung has agreed to provide more than $850M in funding to boot.
- Panacea will be renamed Nuvation Bio; its common stock is expected to remain listed on the New York Stock Exchange under the new ticker symbol (NUVB)
- The company is advancing up to six compounds, and the FDA has signed-off Phase 1/2 study for its lead compound, NUV-422, a CDK2/4/6 inhibitor, in patients with high-grade gliomas, including glioblastoma multiforme. Enrollment will commence in Q1 2021.
- Phase 1/2 dose-escalation and multiple expansion cohort study is expected to enroll ~80 adult patients. The dose-escalation part of the study will evaluate the safety, tolerability and pharmacokinetics of NUV-422. Top-line data from dose-escalation part is expected in 2022
- It plan to submit five additional INDs by 2026 for therapies targeting solid tumors and hematologic cancers.
- https://seekingalpha.com/news/3624427-nuvation-bio-to-go-public-in-combination-blank-cheque-firm-panacea
Wednesday, October 21, 2020
Nuvation Bio to go public in combination with blank check firm Panacea
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.